May 3 (Reuters) - Teva Pharmaceutical Industries Ltd :
* TEVA PHARM CEO SCHULTZ: STILL EXPECT TO SELL $4 BILLION WORTH OF GENERIC DRUGS IN U.S. IN 2018
* TEVA PHARM CEO SCHULTZ: MIGRAINE DRUG LIKELY TO BE APPROVED FOR QUARTERLY DOSAGE
* TEVA PHARM CEO SCHULTZ: NO PLANS TO ISSUE NEW EQUITY, NO PLANS FOR M&A ACTIVITY
* TEVA PHARM: DEVELOPING PEN DEVICE FOR MIGRAINE DRUG BUT NO SPECIFIC DATE FOR LAUNCH
* TEVA PHARM CFO: EXPECTS TO PAY DOWN ANOTHER $1.3-$1.5 BILLION OF DEBT IN 2018
* TEVA PHARM: NO EXPECTATION FOR ANOTHER 40 MG GENERIC VERSION OF COPAXONE IN 2018 Further company coverage: (Reporting by Steven Scheer and Tova Cohen)
